Ernexa Therapeutics, Inc. (ERNA)
2.34
-0.15
(-6.02%)
USD |
NASDAQ |
Oct 09, 16:00
2.34
0.00 (0.00%)
After-Hours: 20:00
Ernexa Therapeutics Enterprise Value : -1.765M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | -1.765M |
| October 07, 2026 | -1.882M |
| October 06, 2026 | -2.063M |
| October 05, 2026 | -1.519M |
| October 02, 2026 | -1.215M |
| October 01, 2026 | -1.215M |
| September 30, 2026 | -0.934M |
| September 29, 2026 | -0.9808M |
| September 28, 2026 | -0.6181M |
| September 25, 2026 | -0.6473M |
| September 24, 2026 | -0.4426M |
| September 23, 2026 | -0.4075M |
| September 22, 2026 | -0.232M |
| September 21, 2026 | -0.0448M |
| September 18, 2026 | -0.1969M |
| September 17, 2026 | -0.2788M |
| September 16, 2026 | -0.1033M |
| September 15, 2026 | 0.0956M |
| September 14, 2026 | 0.3179M |
| September 11, 2026 | 0.1951M |
| September 10, 2026 | 0.0254M |
| September 09, 2026 | 0.0254M |
| September 08, 2026 | 0.2243M |
| September 04, 2026 | 0.3647M |
| September 03, 2026 | 0.6221M |
| Date | Value |
|---|---|
| September 02, 2026 | 0.6338M |
| September 01, 2026 | 0.4115M |
| August 31, 2026 | 0.6689M |
| August 28, 2026 | 0.6689M |
| August 27, 2026 | 0.862M |
| August 26, 2026 | 1.043M |
| August 25, 2026 | 1.084M |
| August 24, 2026 | 1.213M |
| August 21, 2026 | 1.008M |
| August 20, 2026 | 0.6104M |
| August 19, 2026 | 0.5051M |
| August 18, 2026 | 0.2945M |
| August 17, 2026 | 0.0722M |
| August 14, 2026 | 0.3179M |
| August 13, 2026 | 0.353M |
| August 12, 2026 | 0.4934M |
| August 11, 2026 | 0.4583M |
| August 10, 2026 | 0.6221M |
| August 07, 2026 | 0.2477M |
| August 06, 2026 | 0.4232M |
| August 05, 2026 | 0.119M |
| August 04, 2026 | 0.4934M |
| August 03, 2026 | -0.6415M |
| July 31, 2026 | -0.8404M |
| July 30, 2026 | -0.6181M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cerenome, Inc. | 4.542M |
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Alnylam Pharmaceuticals, Inc. | 29.71B |
| Anika Therapeutics, Inc. | 244.19M |
| Savara, Inc. | 849.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.009M |
| Total Expenses (Quarterly) | 4.009M |
| EPS Diluted (Quarterly) | -3.396 |
| Earnings Yield | -808.7% |
| Normalized Earnings Yield | -802.18 |